Skip to main content
RGEDF logo

Chemical Works of Gedeon Richter Plc (RGEDF) Stock Price & Analysis

Chemical Works of Gedeon Richter Plc (RGEDF) — price $40.30 (-3.19%), as of the Nov 19, 2026 trading session; market cap $7.35B.

Educational signal · not a buy or sell recommendation · How to read this

$40.30 −$1.33 (-3.19%) Market Cap $7.35B

Chemical Works of Gedeon Richter Plc · RGEDF

Gedeon Richter PLC is a Hungarian pharmaceutical company specializing in the development and manufacture of pharmaceuticals.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • NVS · Novartis AG · 82 /100
  • SNY · Sanofi · 87 /100
  • ABBV · AbbVie Inc. · 83 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$40.30
Change on the day-3.19%
52-week range$29.23 – $45.28
Market capitalisation$7.35B—
Price / earnings (trailing)10.83
Shares traded on the day100

Price & events

Other perspectives

Council score for Chemical Works of Gedeon Richter (RGEDF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Strong
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Strong
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Chemical Works of Gedeon Richter (RGEDF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Chemical Works of Gedeon Richter Plc (RGEDF) is the company analyzed here. It employs 11,955 people and is led by Gabor Orban. In Q3 FY2026 it reported revenue of HUF 225.13B and net income of HUF 68.61B. The market values it at $7.35B.

2 · Latest results

What do the latest results show for Chemical Works of Gedeon Richter (RGEDF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of HUF 225.13B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026HUF 225.13BHUF 68.61BHUF 375.48 (diluted)
Q2 FY2026HUF 237.57BHUF 37.66BHUF 206.57 (diluted)
Q1 FY2026HUF 219.81BHUF 65.17BHUF 357.22 (diluted)
Q4 FY2025HUF 247.27BHUF 68.60BHUF 376.52 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Chemical Works of Gedeon Richter (RGEDF)?

Short answer · as of

The distress and quality screens read Altman Z 7.34 · Piotroski F 7. Trailing ratios: ROE 16.7% · ROA 13.0% · current ratio 4.69 · earnings yield 9.3% · free-cash-flow yield 10.5%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RGEDF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported RGEDF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Chemical Works of Gedeon Richter (RGEDF)?

Read these with our analysis →

Common Questions About RGEDF

These answers are editorial: 1 of these 8 answers is drawn from the RGEDF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is RGEDF a good stock to buy?

Stock Expert AI does not rate RGEDF buy, sell or hold. Chemical Works of Gedeon Richter Plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RGEDF stock price today?

The last price recorded for Chemical Works of Gedeon Richter Plc (RGEDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is Gedeon Richter PLC's drug pipeline status?

Gedeon Richter PLC has a robust drug pipeline with several products in various stages of clinical trials, particularly in gynecology and central nervous system disorders.

What are the key factors to evaluate for RGEDF?

Evaluate RGEDF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Innovative Drug Development: The company is actively engaged in developing innovative therapies, particularly in the fields of gynecology and central nervous system disorders. Not financial advice.

How frequently does RGEDF data refresh on this page?

RGEDF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RGEDF's recent stock price performance?

Chemical Works of Gedeon Richter Plc (RGEDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong financial performance with high profit and gross margins. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RGEDF overvalued or undervalued right now?

The trailing P/E of Chemical Works of Gedeon Richter Plc (RGEDF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research RGEDF before investing?

Before investing in Chemical Works of Gedeon Richter Plc (RGEDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.